Icagen, Inc. Reports Positive Results for ICA-105665 in Patients With Photosensitive Epilepsy

RESEARCH TRIANGLE PARK, N.C., March 15, 2010 (GLOBE NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) today reported positive results in its Phase IIa epilepsy study of ICA-105665, the Company's novel orally available small molecule KCNQ potassium channel agonist.